Inmune Bio, Inc.
Ebstrocel™
RDEB
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for Ebstrocel™ in RDEB are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“The Company also intends to use the MHRA feedback to inform future interactions with the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) with additional filings planned in late 2026 or early 2027, subject to ”